Fig. 1 · Structure
Documents & Downloads
Lorvotuzumab mertansine
CD56-Targeted ADC
Lorvotuzumab mertansine is an antibody-drug conjugate (ADC) that targets CD56. This compound comprises a humanized N901 monoclonal antibody linked to the cytotoxic maytansinoid DM1 through a stable disulfide bond. Lorvotuzumab mertansine exhibits significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutics. Its targeted action allows for the study of CD56-expressing tumors and the mechanisms of ADC efficacy.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1008106-64-6 |
| Applications | CD56-Targeted ADC |
| Synonyms | IMGN-901; BB-1090 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.